Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0IZJTF)
| ADC Name |
WO2024239281A1 c418
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
C418
Click to Show/Hide
|
|||||
| Organization |
HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD | ZHAO, ROBERT YONGXIN | HANGZHOU DAC BIOTECH CO., LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
vandortuzumab
|
Antibody Info | ||||
| Antigen Name |
Metalloreductase STEAP1 (STEAP1)
|
Antigen Info | ||||
| Payload Name |
undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.038 nM
|
|||
| Method Description |
MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
|
||||
| In Vitro Model | Prostate carcinoma | C4-2B cells | CVCL_4784 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.045 nM
|
|||
| Method Description |
MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
|
||||
| In Vitro Model | Prostate carcinoma | PC3-4H7 cells | Homo sapiens | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.65 nM
|
|||
| Method Description |
MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
|
||||
| In Vitro Model | Prostate carcinoma | 22RV1 cells | CVCL_1045 | ||
References